Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bommareddy, Praveen K., Rabkin, Samuel D., Kaufman, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422399/
https://www.ncbi.nlm.nih.gov/pubmed/30906668
http://dx.doi.org/10.1080/2162402X.2019.1571390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422399/
https://www.ncbi.nlm.nih.gov/pubmed/30906668
http://dx.doi.org/10.1080/2162402X.2019.1571390

Ejemplares similares